EODData

MEMBERSHIP REGISTER LOG IN

FRA, MAH0: Mereo BioPharma Group plc

31 Mar 2026
LAST:

0.2710

CHANGE:
 0.01		OPEN:
0.2710		HIGH:
0.2710		ASK:
0.0000		VOLUME:
0
CHG(%):
2.87		PREV:
0.2790		LOW:
0.2710		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
31 Mar 260.27100.27100.27100.27100
30 Mar 260.27900.27900.27900.27900
27 Mar 260.28800.28800.28800.28800
26 Mar 260.29300.29300.29300.2930550
25 Mar 260.28400.28400.28400.2840550
24 Mar 260.28700.30000.28700.3000550
23 Mar 260.28600.28600.28600.28602.5K
20 Mar 260.30300.30300.30300.30302.5K
19 Mar 260.30800.30800.30800.30800
18 Mar 260.31800.31800.31800.31800

PROFILE

Name:Mereo BioPharma Group plc
About:Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Sector:Healthcare
Industry:Biotechnology
Address:One Cavendish Place, London, United Kingdom, W1G 0QF
Website:https://www.mereobiopharma.com
ISIN:US5894921072
LEI:213800U8JQHIJOS5AS09

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-5.15 
Price to Sales:491.61 
Price to Book:4.53 
Operating Margin:-19.51 
Return on Assets:-0.35 
Return on Equity:-0.75 
Revenue:434.0K 
Shares:159.0M 
Market Cap:43.09M 

TECHNICAL INDICATORS

MA5:0.284.4%
MA10:0.298.1%
MA20:0.3115.8%
MA50:0.3527.7%
MA100:0.89227.2%
MA200:1.31384.3%
RSI14:24.81 
WPR14:-100.00 
MTM14:-0.06
ROC14:-0.19 
ATR:0.01 
Week High:0.3010.7%
Week Low:0.270.0%
Month High:0.3528.0%
Month Low:0.27384.3%
Year High:2.47810.3%
Year Low:0.270.0%
Volatility:21.09